The firm will donate all profits from the sales to the teta&teta association

 

Mango is introducing a new collection of bras, underwear and swimwear garments for women who have undergone a breast mastectomy. The initiative is in response to the challenge laid down last year by the teta & teta association to create a version of Lola, the first single-cup bra.

The aim of the brand is to be able to cater for the needs of women who have had to undergo a mastectomy and who have decided not to use a breast implant or undergo breast reconstruction surgery. A key feature of the project has been to ensure the creation of an affordable product, given the high price of these types of garment at present. Justi Ruano, Mango’s Design Director, commented: “Our community, our customers, are our priority. Listening to them, offering solutions and adapting to their needs”.

The Lola bra has a single cup. The Design team has taken a step further by complementing the offer with alternative formats for breast implants and by increasing product diversity with swimwear as well as underwear garments.

The capsule collection is made up of three bras, two swimsuits and a bikini. The versatile design of all these garments allows them to be adapted for women who have undergone a mastectomy as well as  for women with a breast implant or prosthesis.

The designs, which were made in Spain, will be available worldwide on the mango.com official website in a wide range of sizes, from S to XXXL.

teta&teta is a non-profit making organisation involved in social projects that promote female liberty through creativity and activism. One of its aims is to give a voice to women who have undergone a mastectomy, by normalising such bodies and sharing all that has been learned from their testimonies with brands like Mango, which wants to contribute to the inclusiveness and diversity of its community. All profits from sales of this collection will be donated to this association. On previous occasions, Mango has created solidarity collections, donating all profits to cancer research.